Meeting
2023 ASCO Annual Meeting
Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.
Authors
Milad Ibrahim
New York University, New York, NY
Milad Ibrahim , Paola Angulo , Faisal Fa'ak , Noha Abdel-Wahab , Adi Diab , Janice M. Mehnert , Jeffrey S. Weber , Amanda Lund , Markus Schober , Judy Zhong , Iman Osman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9549)
DOI
10.1200/JCO.2023.41.16_suppl.9549
Abstract #
9549
Poster Bd #
312
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
First Author: Piyush Grover
Poster
2019 ASCO Annual Meeting
Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.
First Author: Suthee Rapisuwon
Poster
2024 ASCO Annual Meeting
Comprehensive whole genome and transcriptome analysis of patients with advanced solid tumor treated with immune checkpoint inhibitor therapy in the pan-cancer cohorts from the Marathon of Hope Cancer Centres Network Study (MOHCCN).
First Author: Khadjah Alshankati
Poster
2023 ASCO Annual Meeting
Exploring the clinical significance of specific immune-related adverse events (irAE) in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
First Author: Nethanel Asher